0000899243-19-010474.txt : 20190410
0000899243-19-010474.hdr.sgml : 20190410
20190410161612
ACCESSION NUMBER: 0000899243-19-010474
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190408
FILED AS OF DATE: 20190410
DATE AS OF CHANGE: 20190410
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOVE TED W
CENTRAL INDEX KEY: 0001188919
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 19741832
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 400 EAST JAMIE COURT, SUITE 101
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-04-08
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001188919
LOVE TED W
C/O GLOBAL BLOOD THERAPEUTICS, INC.
171 OYSTER POINT BLVD., SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
See Remarks
Common Stock
2019-01-31
5
A
0
E
579
36.68
A
1143553
D
Common Stock
2019-04-08
4
M
0
35000
A
1178553
D
Common Stock
2019-04-08
4
F
0
17354
58.51
D
1161199
D
Common Stock
2500
I
By Daughter
Common Stock
2500
I
By Daughter
Restricted Stock Units
2019-04-08
4
M
0
35000
0.00
D
Common Stock
35000
87500
D
Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 35,000 shares of Common Stock underlying the Reporting Person's RSUs.
On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On April 8, 2019, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Chief Executive Officer and President
/s/ Lesley Ann Calhoun , as Attorney-in-Fact
2019-04-10